Martha J. Kelly
Profile
Martha J.
Kelly worked as a Senior Director of Chemistry at Locus Pharmaceuticals, a Senior Scientist at Rohm & Haas Co., and as the Head of Research & Product Development at Madrigal Pharmaceuticals.
She received her undergraduate degree from the College of the Holy Cross in Massachusetts and her doctorate degree from the University of Wisconsin.
Former positions of Martha J. Kelly
| Companies | Position | End |
|---|---|---|
Rohm & Haas Co.
 Rohm & Haas Co. Chemicals: Major DiversifiedProcess Industries Rohm & Haas Co. develops and manufactures specialty chemicals, paints, adhesives, and materials. The company was founded by Otto Röhm and Otto Haas on September 1, 1909 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - |
Madrigal Pharmaceuticals, Inc. /Old/
 Madrigal Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Madrigal Pharmaceuticals, Inc. develops small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. It specializes in the treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis, diabetes, dyslipidemia, and cardiovascular disease. The company was founded by Rebecca A. Taub, Brian N. Cunningham, and Edward Chiang in September 2011 and is headquartered in Fort Washington, PA. | Chief Tech/Sci/R&D Officer | - |
Locus Pharmaceuticals, Inc.
 Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation. | Corporate Officer/Principal | - |
Training of Martha J. Kelly
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
| University of Wisconsin | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 3 |
|---|---|
Locus Pharmaceuticals, Inc.
Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation. | Health Technology |
Rohm & Haas Co.
Rohm & Haas Co. Chemicals: Major DiversifiedProcess Industries Rohm & Haas Co. develops and manufactures specialty chemicals, paints, adhesives, and materials. The company was founded by Otto Röhm and Otto Haas on September 1, 1909 and is headquartered in Philadelphia, PA. | Process Industries |
Madrigal Pharmaceuticals, Inc. /Old/
Madrigal Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Madrigal Pharmaceuticals, Inc. develops small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. It specializes in the treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis, diabetes, dyslipidemia, and cardiovascular disease. The company was founded by Rebecca A. Taub, Brian N. Cunningham, and Edward Chiang in September 2011 and is headquartered in Fort Washington, PA. | Health Technology |
- Stock Market
- Insiders
- Martha J. Kelly
